← United States · Coverage record
US · SEC FORM 4
Celularity Inc
CELU · Nasdaq · CIK 0001752828 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-01-12 · Dragasac Ltd; Genting Berhad; Lim Kok Thay.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 391,276
- Previous report
- 821,020
- Avg daily volume
- 154,929
- Days to cover
- 2.5
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-01-12 | Dragasac Ltd; Genting Berhad; Lim Kok Thay | Purchase (P) | Class A Common Stock | 21,410,983 | USD 0.25 | USD 5,352,746 | SEC filing ↗ |
| 2023-10-05 | Hariri Robert J | Purchase (P) | Class A Common Stock | 9,357,585 | USD 0.16 | USD 1,497,214 | SEC filing ↗ |
| 2023-09-29 | Hariri Robert J | Purchase (P) | Class A Common Stock | 9,064,539 | USD 0.17 | USD 1,540,972 | SEC filing ↗ |
| 2022-11-30 | Hariri Robert J | Purchase (P) | Class A Common Stock | 10,000 | USD 1.72 | USD 17,200 | SEC filing ↗ |
| 2022-11-29 | Hariri Robert J | Purchase (P) | Class A Common Stock | 40,000 | USD 1.71 | USD 68,400 | SEC filing ↗ |
| 2022-11-28 | Hariri Robert J | Purchase (P) | Class A Common Stock | 40,000 | USD 1.74 | USD 69,600 | SEC filing ↗ |
Form 4 evidence
25 transaction lines in the latest 365-day window; 130 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | Hariri Robert J | Option exercise / conversion (M) | Class A Common Stock | 3,281 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-13 | Hariri Robert J | Tax withholding (F) | Class A Common Stock | 1,182 | USD 1.28 | USD 1,513 | SEC filing ↗ |
| 2026-04-13 | Haines John R | Option exercise / conversion (M) | Class A Common Stock | 1,641 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (25 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | Hariri Robert J | Option exercise / conversion (M) | Class A Common Stock | 3,281 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-13 | Hariri Robert J | Tax withholding (F) | Class A Common Stock | 1,182 | USD 1.28 | USD 1,513 | SEC filing ↗ |
| 2026-04-13 | Haines John R | Option exercise / conversion (M) | Class A Common Stock | 1,641 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-13 | Haines John R | Tax withholding (F) | Class A Common Stock | 583 | USD 1.28 | USD 746 | SEC filing ↗ |
| 2026-04-13 | Brigido Stephen | Option exercise / conversion (M) | Class A Common Stock | 821 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-13 | Brigido Stephen | Tax withholding (F) | Class A Common Stock | 268 | USD 1.28 | USD 343 | SEC filing ↗ |
| 2026-01-12 | Parks Diane L. | Award / grant (A) | Class A Common Stock | 30,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | Ling Geoffrey M.D. | Award / grant (A) | Class A Common Stock | 19,231 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | LeVien Vincent | Award / grant (A) | Class A Common Stock | 28,847 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | Diamandis Peter | Award / grant (A) | Class A Common Stock | 20,385 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | Parks Diane L. | Award / grant (A) | Class A Common Stock | 30,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | Ling Geoffrey M.D. | Award / grant (A) | Class A Common Stock | 19,231 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | LeVien Vincent | Award / grant (A) | Class A Common Stock | 28,847 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-12 | Diamandis Peter | Award / grant (A) | Class A Common Stock | 20,385 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-29 | Parks Diane L. | Award / grant (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-29 | Ling Geoffrey M.D. | Award / grant (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-29 | LeVien Vincent | Award / grant (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-29 | Diamandis Peter | Award / grant (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-19 | Parks Diane L. | Award / grant (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-19 | Ling Geoffrey M.D. | Award / grant (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-19 | Diamandis Peter | Award / grant (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-19 | Parks Diane L. | Award / grant (A) | Class A Common Stock | 61,539 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-19 | Ling Geoffrey M.D. | Award / grant (A) | Class A Common Stock | 44,379 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-19 | LeVien Vincent | Award / grant (A) | Class A Common Stock | 3,699 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-19 | Diamandis Peter | Award / grant (A) | Class A Common Stock | 47,042 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | CELU |
| CIK | 0001752828 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 130 transaction lines from 2021-07-16 to 2026-04-13 7 P purchase lines · 2 S sale lines · 121 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.